Investor's Business Daily on MSN

Psychedelics-tied GH skyrockets on FDA go-ahead for depression drug

Biotech stock GH Research catapulted Monday after the FDA gave it the go-ahead to resume testing its depression drug.

A small company can now advance its psychedelic into phase 3. Here’s why that matters to other psychedelic biotechs.

The Irish company is part of a growing class of drugmakers that aim to harness the power of psychedelic compounds against ...